Leptin and adiponectin in the female life course

S.B. Lecke, D.M. Morsch and P.M. Spritzer
Leptin and adiponectin in the female life course

S.B. Lecke, D.M. Morsch and P.M. Spritzer

Unidade de Endocrinologia Ginecológica, Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Laboratório de Endocrinologia Molecular, Departamento de Fisiologia, Universidade Federal do Rio Grande do Sul, and Instituto Nacional de Hormônios e Saúde da Mulher - CNPq, Porto Alegre, RS, Brasil

Abstract

Adipose tissue secretes a variety of adipokines, including leptin and adiponectin, which are involved in endocrine processes regulating glucose and fatty metabolism, energy expenditure, inflammatory response, immunity, cardiovascular function, and reproduction. The present article describes the fluctuations in circulating leptin and adiponectin as well as their patterns of secretion in women from birth to menopause. During pregnancy, leptin and adiponectin seem to act in an autocrine/paracrine fashion in the placenta and adipose tissue, playing a role in the maternal-fetal interface and contributing to glucose metabolism and fetal development. In newborns, adiponectin levels are two to three times higher than in adults. Full-term newborns have significantly higher leptin and adiponectin levels than preterms, whereas small-for-gestational-age infants have lower levels of these adipokines than adequate-for-gestational-age newborns. However, with weight gain, leptin concentrations increase significantly. Children between 5 and 8 years of age experience an increase in leptin and a decrease in adiponectin regardless of body mass index, with a reversal of the newborn pattern for adiponectin: plasma adiponectin levels at age five are inversely correlated with percentage of body fat. In puberty, leptin plays a role in the regulation of menstrual cycles. In adults, it has been suggested that obese individuals exhibit both leptin resistance and decreased serum adiponectin levels. In conclusion, a progressive increase in adiposity throughout life seems to influence the relationship between leptin and adiponectin in women.

Key words: Female; Adiposity; Leptin; Adiponectin

Introduction

Adipose tissue is currently recognized as a dynamic organ because of its capacity to secrete hormones and cytokines. White adipose tissue, the predominant form found in adults (brown fat is mainly found in neonates), consists of preadipocytes and adipocytes, macrophages, endothelial cells, fibroblasts, and leukocytes (1), and secretes a variety of adipokines. These adipokines are involved in a range of endocrine processes that regulate glucose and fatty metabolism, energy expenditure, inflammatory response, immunity, cardiovascular function, and reproduction, among other functions (2,3).

Several aspects related to leptin and adiponectin have been extensively studied, including their metabolic, clinical, and pharmacological characteristics. However, the behavior of these adipokines over the course of life has received less attention. In the present article, fluctuations in circulating leptin and adiponectin as well as their patterns of secretion from birth to menopause are reviewed in order to trace a physiological profile of these adipokines in the female life course.

Leptin and adiponectin

Since its discovery in 1994, leptin has opened a wide field for research on the biology of adipocytes, including their metabolic and endocrine roles as well as the relationships between adipose secretagogues and peripheral tissues. Leptin, the product of the OB gene located at 7q31.3, provides a molecular basis for the lipostatic theory of the regulation of energy balance (4). It has become clear that leptin also plays an important role in reproduction, both during pregnancy and early neonatal life (4). Leptin is produced by adipocytes and also by the placenta (5). It has been shown to act as an afferent satiety signal regulating appetite and weight in humans and rodents (6) by suppressing food intake and increasing energy consumption (2). Leptin circulates as a monomeric 16-kDa protein or bound to leptin-binding proteins.
proteins, forming large, high-molecular weight complexes (7), and acts by interacting with the leptin receptor (Ob-R). The Ob-R family is a large single-transmembrane-domain protein belonging to the class I cytokine receptor family (8,9). The Ob-R gene encodes at least five alternatively spliced variants. The long form of Ob-R is considered to be the active leptin receptor, while the shorter forms lack the membrane-spanning region and are believed to be involved in leptin transport (10) (Figure 1). Ob-R is found in regions of the hypothalamus, the gonadotropic cells of the anterior pituitary gland, the ovarian interstitial cells, the theca and granulosa cells of ovarian follicles, the endometrium, and the Leydig cells of the seminiferous tubules (11). Moreover, Ob-R has been identified in the kidneys, heart, lungs, liver, and skeletal muscle (12).

Adiponectin was first discovered in 1995 as a protein released exclusively by adipose tissue (13). Because it was found simultaneously by several laboratories, adiponectin received various names - adipocyte complement-related protein of 30 kDa (Acrp30), adipose-specific gene adipQ (AdipoQ), adipose most abundant gene transcript 1 (apM1), and gelatin-binding protein of 28 kDa (GBP28) (14). Adiponectin is the protein product of the APM1 gene transcript, which is located on chromosome 3q27, close to the locus for type II diabetes and adiposity (15). This adipokine is secreted by adipose tissue as a low molecular weight trimer, as a combination of two middle molecular weight trimers, or as six high molecular weight (HMW) trimers, and circulates either as a trimer or an oligomer (Figure 2). HMW forms are the predominant and active forms in human serum (16). Adiponectin increases fatty acid oxidation in adipose tissue, liver and muscle, enhancing insulin sensitivity, and inhibits inflammatory mediators and the expression of adhesion molecules within the vascular wall, lowering atherogenic risk (1,16). Adiponectin receptors have been identified predominantly in muscle (AdipoR1) and liver cells (AdipoR2), although in humans they are expressed ubiquitously in the body and brain (2,14,17).

In most studies, circulating levels of leptin and adiponectin have been determined by enzyme-linked immunosorbent assays or enzyme immunoassay, or, alternatively, by radioimmunoassay (associated or not with in-house techniques). While many studies have described assay sensitivity and intra- and interassay coefficients of variation, quality control measurements have been rarely reported.

Pregnancy and intrauterine and neonatal development

During pregnancy, development of the neonate is influenced by critical interactions among genes, epigenetic changes, hormones, nutrition, the intrauterine environment, and early pre- and postnatal events. It has been reported that the increased leptin levels found in pregnant women result from placental secretion, in addition to adipose tissue production (5,18). The higher leptin levels that occur during pregnancy have also been attributed to weight gain and to an increase in body mass index (BMI), as well as to changes in levels of hormones that might stimulate leptin secretion (e.g.,
Leptin and adiponectin in females

Inadequate (high or low) nutrition during fetal and postnatal periods may have long-lasting effects on the development of obesity and related metabolic disorders. Animal studies have shown that exposure to undernutrition during fetal and postnatal periods can lead to leptin resistance (32,33). A series of epidemiological studies have suggested a possible role of leptin in the early development of insulin resistance (30). However, as weight gain progressed, leptin concentrations increased significantly (5,19,31). It has been speculated that these increased leptin levels may derive from the increase in adipose tissue, which is atrophic in adults. In this regard, other investigators have reported a positive association between cord blood adiponectin levels and birth weight, BMI, birth weight-to-length ratio, and leptin levels (25,26), even though this was not confirmed by others (27). Some studies have also provided evidence that high concentrations of leptin can be found in the cord serum of full-term newborns, being closely related to birth weight and fat accumulation (28,29). These findings imply that the relationship between leptin and body fat mass may develop early in life.

Previous studies of preterm infants have shown that serum leptin concentrations were significantly lower than those found in appropriate-for-gestational-age neonates (30). However, as weight gain progressed, leptin concentrations increased significantly (5,19,31). It has been speculated that these increased leptin levels may derive from the increase in adipose tissue typically observed in the under-nutrition period in preterm infants, suggesting a possible involvement of leptin in the early development of insulin resistance (32,33). A series of epidemiological human and experimental animal studies have shown that exposure to inadequate (high or low) nutrition during fetal and postnatal life, as well as reduced fetal growth followed by excessive postnatal catch-up in height and particularly, in weight, increase the risk of obesity, insulin resistance and type 2 diabetes in childhood and adult life (34). The decrease in adiponectin that occurs in small-for-gestational-age infants with the greatest weight catch-up has also been reported as a risk factor for subsequent development of visceral fat and insulin resistance (17,26).

Disturbances in fetal nutrient supply affect adipocyte levels. Muhlhauser and Smith (34) have proposed that prenatal over-nutrition promotes growth of the subcutaneous fat depot, leading to increased leptin secretion and serum levels. In fact, hyperleptinemia during neonatal life may program leptin resistance via dual effects on food intake and energy expenditure, with long-term adverse consequences for the hypothalamic circuits regulating energy balance (2,35). Some studies have shown an increased risk for obesity and insulin resistance in neonates born to obese mothers, as well as higher levels of leptin and markers of inflammation than in infants born to lean mothers (36).

A study of 100 mother/newborn pairs has tried to determine the production of leptin in the uterus and its role in neonatal development. Although maternal serum leptin concentrations correlated with measures of pre- and post-gestational adiposity, there was no association between serum leptin levels in the newborn, an observation confirmed by others (5,9). Interestingly, Hassink et al. (5) demonstrated that 13% of newborns had higher serum leptin concentrations than their mothers, suggesting that the fetus may produce its own leptin, with associated leptin resistance, and/or that the placenta is the main source of leptin production for the fetus. However, Ho et al. (30) have shown a correlation between neonatal serum leptin concentrations and maternal weight and BMI within 24 hours of birth, suggesting that maternal and even placental production of leptin may be involved in the early regulation of fetal metabolism and growth. As in previous studies, no association was demonstrated between neonatal adiponectin levels and maternal age or pre-pregnancy BMI, suggesting that neonatal adiponectin levels are largely independent of maternal influence (25). Bozzola et al. (32) evaluated both total and isoform adiponectin circulating levels in a cohort of infants, and found a significant increase from birth up to the first month of life, followed by a decline at one year of age in all subjects. The investigators argued that the observed fall in serum adiponectin levels may be a consequence of increased adiposity, confirming the negative association between serum adiponectin levels and percentage of body fat, as is the case in older children (32).

Childhood and puberty

Obesity and its associated metabolic and psychological comorbidities have become a major health problem in children.
Between 5 and 8 years of age, metabolic health appears to improve regardless of BMI, with an increase in leptin and a decrease in adiponectin (37). In fact, adiponectin levels in childhood show a marked reversal of the positive body mass correlations observed during the neonatal period: plasma adiponectin levels at age 5 are inversely correlated with percentage of body fat. This inverse association between BMI and adiponectin becomes even more marked in older children (26,38). Previous studies in children of different ethnicities have reported that low plasma adiponectin concentrations were closely related to hyperinsulinemia (38,39), leading to a long-term increased risk for diabetes.

There is a developmental increase in adipose tissue leptin expression and secretion during childhood, reaching maximal capacity in puberty/adulthood. Leptin may be regarded as a link between food intake, energy expenditure and the reproductive system. A possible interpretation is that leptin may signal to the body that energy reserves are adequate for reproduction, representing one of the primary mechanisms linked to the onset of puberty (11,12,40). In fact, a minimal leptin concentration is necessary to activate the hypothalamus-pituitary-gonadal axis, triggering puberty and maintaining reproductive function.

The temporal correlation between increases in leptin concentration and the initiation of luteinizing hormone (LH) pulsatility over peripuberty has been studied in several species. It is well recognized that leptin stimulates the gonadotropin-releasing hormone (GnRH) pulse generator and in turn LH pulses. This adipokine is secreted in a pulsatile manner in ovulatory women: a peak at night followed by a gradual change in LH pulsatility, reaching a nadir in the morning (7,41). In turn, in polycystic ovary syndrome (PCOS), a condition associated with androgen excess and chronic anovulation, circulating leptin seems to be related to the overall and central adiposity that is frequently associated with this syndrome (42). In fact, data from our group suggest that the attenuation of the response of LH to GnRH in obese PCOS women may be related to changes in GnRH oscillator activity caused by a leptin-resistant state (42).

Interestingly, the nightly leptin peak has been associated with acute changes in LH pulses in normal ovulatory women, followed by a decline in metabolic rate (41). These data suggest that a single metabolic cycle regulates the leptin peak and the slowing of LH and metabolic rate. Conversely, both leptin resistance/hyperleptinemia, as observed in obesity and PCOS (42), and decreased circulating leptin, as observed in women with nutritional disorders or athletes, are associated with impaired gonadal steroidogenesis and reproduction (12). The role of leptin in the regulation of the menstrual cycles is further supported by studies demonstrating that menstrual irregularities and amenorrhea are common in women with very high or very low leptin levels (11,19). Evidence suggests that leptin functions as a permissive, rather than a direct triggering factor at the onset of puberty, working in concert with other metabolic signals, such as insulin and insulin-like growth factor, amino acids, and neuropeptides (2,12,19).

### Adulthood and postmenopause

In adults, circulating levels of leptin increase in the presence of total and central obesity and in metabolic disturbances (12,42,43), while adiponectin levels are inversely associated with the degree of adiposity. It has been suggested that obese individuals exhibit both leptin resistance, which antagonizes the metabolic action of insulin, and decreased serum adiponectin levels, increasing the risk for type 2 diabetes, coronary artery disease and metabolic syndrome (44).

Leptin concentrations may vary during the physiological

<table>
<thead>
<tr>
<th>Phase of life</th>
<th>Leptin</th>
<th>Adiponectin</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td>22,24-30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small-for-gestational-age and/or undernourished</td>
<td>↓</td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td>Adequate-for-gestational-age</td>
<td>↔</td>
<td>↔</td>
<td></td>
</tr>
<tr>
<td>Large-for-gestational-age and/or overnourished</td>
<td>↑↑</td>
<td>↑↑</td>
<td></td>
</tr>
<tr>
<td>Childhood</td>
<td>↔</td>
<td>↔</td>
<td>26,32,37,38</td>
</tr>
<tr>
<td>Puberty</td>
<td>↑</td>
<td>↔</td>
<td>11,12,40</td>
</tr>
<tr>
<td>Adulthood</td>
<td></td>
<td></td>
<td>12,42-44</td>
</tr>
<tr>
<td>Lean women</td>
<td>↔</td>
<td>↔</td>
<td></td>
</tr>
<tr>
<td>Overweight/obese women</td>
<td>↑</td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td>Post-menopause</td>
<td></td>
<td></td>
<td>55-57,60</td>
</tr>
<tr>
<td>Lean women</td>
<td>↔</td>
<td>↑↓</td>
<td></td>
</tr>
<tr>
<td>Overweight/obese women</td>
<td>↑</td>
<td>↓</td>
<td></td>
</tr>
</tbody>
</table>

↑ = increased; ↓ = decreased; ↔ = no alteration; ↑↓ = not established.
menstrual cycle, exhibiting a monthly rhythm in ovulatory women. These variations are related to hormone changes, especially those of serum estradiol concentration along the cycle, despite the absence of variation in total body fat and weight (45). Previous studies on middle-aged, normoweight ovulatory women demonstrated that serum leptin levels were significantly lower during the follicular phase of the menstrual cycle as compared to the midcycle and luteal phases (46). Hardie et al. (47) have also demonstrated higher serum leptin concentrations during the luteal phase. However, as observed by our group, adult women show great variability in leptin levels that may mask the subtle differences observed in phases of the menstrual cycles [12.7 (6.2-16.9) vs 8.6 (3.5-22.9) ng/mL in the follicular vs luteal phase, respectively, P = 0.436] (48). As is the case for circulating leptin, food intake also exhibits a similar monthly rhythm in ovulatory women, as documented in the premenstrual dysphoric syndrome: a nadir around the time of ovulation when estrogen is elevated, and an increase following ovulation and during the luteal phase, when progesterone is dominant (49,50).

Asimakopoulos et al. (46) have not found an association between serum adiponectin levels, sex steroids, and other adipokines in middle-aged, normoweight ovulatory women, demonstrating that mean adiponectin concentrations remained practically stable during the menstrual cycle. In addition, no significant changes in serum adiponectin concentrations were reported by Kleiblova et al. (51) in relation to sex hormones or to the degree of insulin sensitivity during the menstrual cycle. In this regard, Rouen et al. (52) observed no variation in adiponectin secretion during the menstrual cycle. These findings suggest that adiponectin is probably not related to reproductive functions in adult women. However, Galvan et al. (53) reported that serum adiponectin concentrations were lower in the postovulatory phase in healthy ovulatory women.

The way leptin and adiponectin regulate metabolic homeostasis is different in some aspects and complementary in others (54). Numerous factors, including body weight and fat composition, insulin resistance and associated metabolic disturbances, diet, and physical activity, are believed to play a role in serum leptin and adiponectin concentrations (11,12,44).

Evidence suggests that the risk for insulin resistance increases after menopause, and that it may be related to the decline in estrogen (53) and may be predominantly influenced by BMI (55,56). In fact, postmenopausal accumulation of abdominal fat and obesity promote abnormal adipokine secretion, particularly increasing serum leptin levels, and contribute to insulin resistance (57). Adipose tissue accumulation in the abdominal cavity has been proposed as a mediator of obesity-related metabolic disorders (58), leading to the development of components of the metabolic syndrome and further enhancing postmenopausal cardiovascular risk in women.

There are contradictory reports regarding serum adiponectin levels after menopause: some reported a decrease (55), while others found no change (57) or even detected increased serum adiponectin concentrations (59). In a cross-sectional study with amenorrheic Mexican women presenting climacteric symptoms and not on hormone replacement therapy, serum adiponectin levels showed no significant variation when compared with those of women with normal menstrual cycles (60). In addition, serum adiponectin levels were significantly decreased, whereas serum leptin levels were increased in obese postmenopausal women compared to normoweight women (57). Adiponectin concentration appears to be higher in normoweight than in overweight women in early postmenopause (52). Taken together, these data support the idea of an inhibitory role for both estrogen and body fat composition in the secretion of this adipokine.

In conclusion, a progressive increase in adiposity throughout life seems to influence the relationship between leptin and adiponectin in women: serum adiponectin levels decrease, while circulating leptin levels markedly increase with body fat mass (Table 1, Figure 3). Moreover, leptin levels appear to be synchronous with hormone fluctuations and metabolic needs throughout the menstrual cycle, promoting

Figure 3. Serum levels of leptin and adiponectin in different phases of the female life course. Serum adiponectin concentrations decrease, while serum leptin levels markedly increase with adiposity.
an interaction between the reproductive system, food intake and energy expenditure. Further studies are warranted to elucidate the relevance of leptin and adiponectin to fetal/neonatal development, as well as possible interactions of these adipokines with fetal/neonatal growth and energy homeostasis. Also, while the role of leptin in puberty onset is well established, possible interactions between adiponectin and reproduction have yet to be elucidated.

References

26. Lindsay RS, Walker JD, Havel PJ, Hamilton BA, Calder AA, Johnstone FD. Adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care 2003; 26: 2244-2249.
29. Ho SP, Wang LJ, Cheng I, Chen YL, Sung TC, Jow GM, et al. Research supported by CNPq (INCT #573747/2008-3), CAPES (#1289/05) and Fundo de Apoio à Pesquisa do Hospital de Clínicas de Porto Alegre (FiPE-HCPA #340/2004), Brazil.


